Hikma Pharmaceuticals PLC 2015 AR2
The report highlights Hikma Pharmaceuticals PLC's performance and strategic progress in 2015, during which the company achieved a revenue of $1,440 million. Key achievements included the acquisition of Roxane Laboratories to transform its US generics business and the acquisition of EIMC United Pharmaceuticals to strengthen its oncology position in Egypt. In sustainability, the company successfully resolved the US FDA Warning Letter at its Portuguese facility and reported its Scope 1 and Scope 2 greenhouse gas emissions. Additionally, Hikma launched a Women Empowerment programme across its global markets and continued its commitment to the UN Global Compact.
Company: Hikma Pharmaceuticals PLC
Sector: Manufacturing
Country: United Kingdom
Year: 2015
Type: AR2
Pages: 198
Back to company
Hikma Pharmaceuticals PLC
Annual Report
The report highlights Hikma Pharmaceuticals PLC's performance and strategic progress in 2015, during which the company achieved a revenue of $1,440 million. Key achievements included the acquisition of Roxane Laboratories to transform its US generics business and the acquisition of EIMC United Pharmaceuticals to strengthen its oncology position in Egypt. In sustainability, the company successfully resolved the US FDA Warning Letter at its Portuguese facility and reported its Scope 1 and Scope 2 greenhouse gas emissions. Additionally, Hikma launched a Women Empowerment programme across its global markets and continued its commitment to the UN Global Compact.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2015
Reporting Period
Jan 1, 2015 - Dec 31, 2015
Fiscal Year
2015
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Women on Board
Women in Management
Employees